Keyphrases
Podocyte Injury
69%
Focal Segmental Glomerulosclerosis
60%
Kidney
55%
Podocyte
53%
Glomerular Disease
48%
Yes-associated Protein 1 (YAP1)
43%
Hippo Pathway
27%
Novel Treatments
25%
Plasminogen
25%
Treatment Paradigms
25%
Lumasiran
25%
Hyperoxaluria
25%
Kidney Disease
22%
Protein Signaling
18%
Kidney Failure
18%
HIV-associated Nephropathy (HIVAN)
17%
End-stage Kidney Disease
15%
Dendrin
15%
Nephropathy
15%
Proteinuria
15%
Nephrotoxicity
14%
Kidney Disease Progression
13%
IgA Nephropathy (IgAN)
13%
RNA Interference
13%
Metformin
12%
Lupus Nephritis
12%
Disease Progression
12%
Osmotic Demyelination Syndrome
12%
Targeted Therapy
12%
International Reports
12%
Coronavirus Disease (COVID)
12%
Ablation
12%
Post-acute Sequelae of COVID-19 (PASC)
12%
Post-COVID Symptoms
12%
Molecular Analysis
12%
AMP Kinase
12%
Mechanism of Action
12%
KIBRA
12%
Kinase Activation
12%
ETA Receptor
12%
Placebo-controlled Randomized Trial
12%
Edema
12%
Marker of Disease Progression
12%
Issue 1
12%
Collapsing Glomerulopathy
12%
Pharmacokinetics
12%
Dasatinib
12%
Patient-specific
12%
Multidisciplinary Perspective
12%
Vaccination
12%
Medicine and Dentistry
Podocyte
100%
Glomerulopathy
59%
Focal Segmental Glomerulosclerosis
48%
Injury
36%
Urinary System
34%
Renal Failure
30%
Signaling Protein
27%
Phosphotransferase
26%
Disease Exacerbation
26%
Fibrinolysin
25%
Lumasiran
25%
Primary Hyperoxaluria
25%
Piperazine Estrone Sulfate
23%
Placebo
21%
HIV-associated Nephropathy
18%
End Stage Renal Disease
17%
Biological Marker
17%
Plasminogen
17%
Nephropathy
17%
COVID-19
15%
Proteinuria
15%
Hippo Signaling
15%
Upregulation
15%
Actin
14%
Nephrotoxicity
14%
Immunoglobulin A Nephropathy
14%
RNAi Therapeutics
13%
Oxalic Acid
13%
4 Iodo 2,5 Dimethoxyamphetamine
12%
Glycon
12%
Edema
12%
Receptor
12%
Targeted Therapy
12%
Angiotensin 1 Receptor Antagonist
12%
Osmotic Demyelination Syndrome
12%
Interstitial Nephritis
12%
Kidney Dysfunction
12%
Lifespan
12%
Adenosine Phosphate
12%
Brain Protein
12%
Lupus Nephritis
12%
Human Immunodeficiency Virus
12%
Embryo Development
12%
Receptor Antagonist
12%
Atrasentan
12%
Randomized Controlled Trial
12%
Dasatinib
12%
Pharmacokinetics
12%
Randomized Clinical Trial
12%
Sequela
12%